Yubo Biotech dismisses auditor MTS CPA due to president's retirement, hires HHL Advisors as successor

Yubo International Biotech Ltd

Dismissal of Michael T. Studer CPA P.C. effective Jan 2, 2025; prior auditor's reports contained a going concern explanatory paragraph.
No disagreements or reportable events occurred during fiscal years 2022, 2023, or the interim period through Dec 26, 2024.
Engagement of HHL Advisors Group as new independent registered public accounting firm, effective Jan 2, 2025, approved by board.
Neither the company nor anyone on its behalf consulted HHL on accounting principles or audit opinions prior to engagement.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Yubo International Biotech Ltd dismissed Michael T. Studer CPA P.C. as its auditor.

Action: dismissal
Auditor: Michael T. Studer CPA P.C.
Successor: HHL Advisors Group

Exact text from the filing

On December 26, 2024, Yubo International Biotech Limited, a New York corporation (the “Company”), dismissed Michael T. Studer CPA P.C. (“MTS CPA”) as the Company’s independent registered public accounting firm

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Yubo International Biotech Ltd engaged HHL Advisors Group as its auditor.

Action: engagement
Auditor: HHL Advisors Group

Exact text from the filing

On December 26, 2024, the Company engaged HHL Advisors Group (“HHL”) as its new independent registered public accountant, effective January 2, 2025.

View on SEC.gov

47 auditor changes filed in the last 30 days. Browse all auditor changes →

Yubo International Biotech Ltd filing history →

Source: SEC EDGAR

accession 0001640334-25-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.